Epac:新的支气管哮喘治疗靶分子  

Epac protein:anovel target of the bronchial asthma management

作　　者：韩曙光[1] 赵弘卿[1] 

机构地区：[1]无锡市第二人民医院呼吸科,214002

出　　处：《中华哮喘杂志（电子版）》2013年第6期54-57,共4页Chinese Journal of Asthma(Electronic Version)

摘　　要：环磷酸腺苷(cyclic adenosine monophosphate,cAMP)是最早阐明参与细胞内信号转导的第二信使。cAMP参与调控人类多种病理生理过程,如代谢、钙调控、学习和记忆、细胞生长与分化、凋亡及炎症等。一直以来,蛋白激酶A(protein kinase A,PKA)被认为是cAMP发挥生物学作用的惟一靶分子。最近研究发现Epac蛋白,一种新的cAMP靶分子,可以单独或与PKA协同实现cAMP多种生物学效应。本文主要阐述Epac在支气管哮喘治疗中的作用及其可能的机制,为探索支气管哮喘新的治疗标靶提供有益的线索。Cyclic adenosine monophosphate （cAMP） is the firstly discoveried second messenger. cAMP controls a range of diverse physiological processes, including metabolicevents, calcium handling, learning and memory, cellgrowth and differentiation, apoptosis, and inflammation. Protein kinase A （PKA） had been considered as the sole downstream target of cAMP. However, recent studies have demonstrated thatEpac, a novel cAMPmediator, regulates manyphysiological processes either alone and （or） in concert with PKA. In this review, we will discuss the roles and probable mechanisms of Epac in the management of asthma in order to provide beneficial clue to find new therapy targets.

关 键 词：支气管哮喘 Epac G蛋白耦联受体 环磷酸腺苷 蛋白激酶A 

分 类 号：R562.25[医药卫生—呼吸系统]